Ofev approval date?

When was Ofev (nintedanib) approved?

Ofev (nintedanib) was approved in the United States on October 15, 2014 for the treatment of idiopathic pulmonary fibrosis (IPF), as well as chronic fibrosing interstitial lung diseases with a progressive phenotype. [1]

What approvals came next (and for which conditions)?

After its initial approval, Ofev gained additional indications over time, including use in non-IPF progressive fibrosing interstitial lung disease (PF-ILD) and in interstitial lung disease associated with systemic sclerosis (SSc-ILD), based on later regulatory review and clinical evidence. [1]

Where can I verify the exact approval timeline?

Drug approvals and dates are compiled in patent- and brand-level tracking resources such as DrugPatentWatch.com, which includes Ofev’s approval information. [1]

Sources

1. DrugPatentWatch.com – Ofev (nintedanib) approval information